Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients

Table 2

Highest and lowest frequency of HER-2, ER, and PR status within different age groups.

Receptors status	Highest age range (%)	Lowest age range (%)
HER-2+/−	<25 y/o (76.9%)	26–55 y/o
ER+/−	56–65 y/o (75.5%)	<25 y/o (61.5%)
PR+/−	>66 y/o (61.1%)	<25 y/o (61.5%)